EGFR and head and neck squamous cell carcinoma: To this day, anti-EGFR treatment with cetuximab has been the only targeted therapy shown to substantially improve HNSCC patient outcome, although its superiority over Cisplatin when combined with irradiation as first-line therapy for locally advanced, non-metastatic HNSCC is increasingly questioned based on recent clinical data [42].